May 22, International Day of Biodiversity.
----------------------------
Chromosome BITIBAjK
----- -----------------------
Saturday, May 21, 2011
Dental Makeover Contest In Ohio
WE WOMEN FIGHTING THE "Agreal-ACLIMAFEL-AGRADIL .." DISEASES THAT WE PRODUCED THE POISON "Learn how to acquired diseases that attack humans.
Print
Learn how he acquired some diseases that attack humans.
by Sanofi Pasteur.
In nature there are factors that make our health is compromised, it is influenced by climate change, the area where we are, at random, and even by our lack of hygiene .... -----------------------------------
AND
CONCEALMENT OF SCIENTIFIC RESEARCH, ON THE HUMAN USE DRUGS AS THEY DID WITH:
veralipride-veralipride.
Learn how he acquired some diseases that attack humans.
by Sanofi Pasteur.
In nature there are factors that make our health is compromised, it is influenced by climate change, the area where we are, at random, and even by our lack of hygiene .... -----------------------------------
AND
CONCEALMENT OF SCIENTIFIC RESEARCH, ON THE HUMAN USE DRUGS AS THEY DID WITH:
veralipride-veralipride.
Prywatne Serwery Tibi 7.6
maximum penalty for counterfeit drugs - LIMA
Print
maximum penalty for counterfeit drugs.
a pharmacist and two more machines used to produce handicrafts and other medicines bamba blisters • Ugarte Ubilluz congratulated Police work and announced that it will continue the process until you know the sentence
Health Minister Oscar Ugarte Ubilluz demanded the maximum penalty 15 years of prison sentence, which establishes the Penal Code against three people, including a pharmacist, arrested yesterday by the National Police in Chorrillos and San Martín de Porres, for machines to produce fake drugs and to craft at risk the health and lives of the population.
"This is the first capture made after the enactment of the amending some of its articles now typify these crimes, which constitute an attack against life and health our population, " revealed after congratulating the staff of the Division of Criminal Investigation and other frauds of the National Police capture.
Those arrested were identified as a pharmacist Rómulo Elías Chirito Jara (69), San Martín de Porres, the brothers José Antonio (42) and Joseph Lizardo Velarde Munoz (44) in Chorrillos, who are accused by the prosecution for alleged offenses against public health and against property - fraud.
"In this case is the maximum penalty provided for in Penal Code, which is 15 years imprisonment, as there is an aggravating factor, because the primary responsibility for the development of these drugs Counterfeit is a chemical pharmacist by profession, knows the dangers to set out the health and lives of those who use counterfeit drugs, "he said.
Article 294 in its point 'C' states that the commission of these crimes will be punished aggravated sentences of eight to fifteen years of imprisonment.
Monitor processes
Ubilluz Ugarte also expressed their commitment to remain vigilant in the process will be followed by the defendants, so that his crime does not go unpunished and said it will continue to support the work of the police against organizations involved in illegal drug trade.
"I want to publicly express my appreciation to the work done by the police because it is the first capture under the new legal framework, which is why we remain vigilant and continue to monitor investigation and judicial process to be opened only after obtaining the conviction to be issued by the judge, "said .
http://www.pysnnoticias.com/2011/05/20/pena-maxima-para-falsificadores-de-medicamentos/
maximum penalty for counterfeit drugs.
a pharmacist and two more machines used to produce handicrafts and other medicines bamba blisters • Ugarte Ubilluz congratulated Police work and announced that it will continue the process until you know the sentence
Health Minister Oscar Ugarte Ubilluz demanded the maximum penalty 15 years of prison sentence, which establishes the Penal Code against three people, including a pharmacist, arrested yesterday by the National Police in Chorrillos and San Martín de Porres, for machines to produce fake drugs and to craft at risk the health and lives of the population.
"This is the first capture made after the enactment of the amending some of its articles now typify these crimes, which constitute an attack against life and health our population, " revealed after congratulating the staff of the Division of Criminal Investigation and other frauds of the National Police capture.
Those arrested were identified as a pharmacist Rómulo Elías Chirito Jara (69), San Martín de Porres, the brothers José Antonio (42) and Joseph Lizardo Velarde Munoz (44) in Chorrillos, who are accused by the prosecution for alleged offenses against public health and against property - fraud.
"In this case is the maximum penalty provided for in Penal Code, which is 15 years imprisonment, as there is an aggravating factor, because the primary responsibility for the development of these drugs Counterfeit is a chemical pharmacist by profession, knows the dangers to set out the health and lives of those who use counterfeit drugs, "he said.
Article 294 in its point 'C' states that the commission of these crimes will be punished aggravated sentences of eight to fifteen years of imprisonment.
Monitor processes
Ubilluz Ugarte also expressed their commitment to remain vigilant in the process will be followed by the defendants, so that his crime does not go unpunished and said it will continue to support the work of the police against organizations involved in illegal drug trade.
"I want to publicly express my appreciation to the work done by the police because it is the first capture under the new legal framework, which is why we remain vigilant and continue to monitor investigation and judicial process to be opened only after obtaining the conviction to be issued by the judge, "said .
http://www.pysnnoticias.com/2011/05/20/pena-maxima-para-falsificadores-de-medicamentos/
Lip Hurts From Chewing Tobacco
AEMPS Briefing Note on buflomedil (Lofton ®): suspension of marketing
Print
AEMPS Briefing Note on buflomedil (Lofton ®): suspension of marketing.
Publication Date: May 20, 2011
Category: DRUGS FOR HUMAN USE, SAFETY.
Reference: MUH (FV) 06/2011
• The English Agency for Medicines and Health Products announced the suspension of marketing of buflomedil (Lofton ®) from 15 July 2011.
• No new treatments should be initiated Lofton ® and proceed to review the treatment of patients currently using this medication.
• No need to interrupt patients treatment until they come to consult your doctor.
The English Agency for Medicines and Medical Devices (Competent Authority) informed healthcare professionals about the suspension of marketing next buflomedil (Lofton ®).
Buflomedil is a peripheral vasodilator, approved in Spain in 1980 in the form of tablets and oral solution droplets. Its licensed indication is the symptomatic treatment of intermittent claudication in peripheral arterial occlusive disease stage II (see data sheet Lofton ®).
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) comprising representatives of all European national agencies, has recommended the suspension of marketing in Europe buflomedil medicines containing as active ingredient. This recommendation has been adopted after the reassessment of the benefit-risk (arbitration).
The arbitration proceedings began after the February 2011 suspension marketed in France. This suspension was due to the occurrence of serious adverse neurological and cardiac, in some cases fatal. These adverse reactions were related to accidental or intentional overdose of medication, even after the country adopted measures to reduce the risk of overdose with the drug.
For this review, the CHMP considered all available data on the benefits and risks of buflomedil, including the assessment carried out in France, data clinical trials, notifications of suspected adverse reactions and information from the literature.
The CHMP has concluded that the measures in France have not prevented the occurrence of overdoses and buflomedil has limited benefit for patients in terms of improving walking distance. Therefore, considered that expected benefits may not outweigh the potential risks.
The Commission shall publish the relevant decision to the conditions of the suspension of marketing.
Regarding the situation in Spain, the Competent Authority reports the following:
• marketing suspension Lofton ® tablets and oral solution drops Spain will become effective on 15 July, the date from which you can not prescribe or dispense the drug.
• To date, no new treatments should be initiated Lofton ® and proceed to review the treatment of patients currently using this medicine, taking into account the current recommendations for treating this disease is based primarily on smoking cessation, exercise and establishment of adequate antiplatelet therapy.
• It is imperative that patients discontinue the treatment until you come to the consulting your doctor.
Available the press release and document questions and answers on its website EMA (www.ema.europa.eu).
Finally recalls the importance of reporting all suspected adverse reactions to the Centre for Pharmacovigilance Autonomy.
Date updated: May 20, 2011
AEMPS Briefing Note on buflomedil (Lofton ®): suspension of marketing.
Publication Date: May 20, 2011
Category: DRUGS FOR HUMAN USE, SAFETY.
Reference: MUH (FV) 06/2011
• The English Agency for Medicines and Health Products announced the suspension of marketing of buflomedil (Lofton ®) from 15 July 2011.
• No new treatments should be initiated Lofton ® and proceed to review the treatment of patients currently using this medication.
• No need to interrupt patients treatment until they come to consult your doctor.
The English Agency for Medicines and Medical Devices (Competent Authority) informed healthcare professionals about the suspension of marketing next buflomedil (Lofton ®).
Buflomedil is a peripheral vasodilator, approved in Spain in 1980 in the form of tablets and oral solution droplets. Its licensed indication is the symptomatic treatment of intermittent claudication in peripheral arterial occlusive disease stage II (see data sheet Lofton ®).
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) comprising representatives of all European national agencies, has recommended the suspension of marketing in Europe buflomedil medicines containing as active ingredient. This recommendation has been adopted after the reassessment of the benefit-risk (arbitration).
The arbitration proceedings began after the February 2011 suspension marketed in France. This suspension was due to the occurrence of serious adverse neurological and cardiac, in some cases fatal. These adverse reactions were related to accidental or intentional overdose of medication, even after the country adopted measures to reduce the risk of overdose with the drug.
For this review, the CHMP considered all available data on the benefits and risks of buflomedil, including the assessment carried out in France, data clinical trials, notifications of suspected adverse reactions and information from the literature.
The CHMP has concluded that the measures in France have not prevented the occurrence of overdoses and buflomedil has limited benefit for patients in terms of improving walking distance. Therefore, considered that expected benefits may not outweigh the potential risks.
The Commission shall publish the relevant decision to the conditions of the suspension of marketing.
Regarding the situation in Spain, the Competent Authority reports the following:
• marketing suspension Lofton ® tablets and oral solution drops Spain will become effective on 15 July, the date from which you can not prescribe or dispense the drug.
• To date, no new treatments should be initiated Lofton ® and proceed to review the treatment of patients currently using this medicine, taking into account the current recommendations for treating this disease is based primarily on smoking cessation, exercise and establishment of adequate antiplatelet therapy.
• It is imperative that patients discontinue the treatment until you come to the consulting your doctor.
Available the press release and document questions and answers on its website EMA (www.ema.europa.eu).
Finally recalls the importance of reporting all suspected adverse reactions to the Centre for Pharmacovigilance Autonomy.
Date updated: May 20, 2011
Hifonics Subs Model Number
Saludcoop Mails
Print
The Saludcoop Post
By: Sonia Rodriguez
Hundreds of documents, emails, conversations and telephone conversations Menssenger are part of the investigation that the search block carousel has on Saludcoop health.
RCN Radio met more than a hundred submissions that are reviewed by experts in accounting, economics, finance, international banking and healthcare.
Among the documents are e-mails between Saludcoop president, Carlos Palacino, and his closest collaborators, especially his law clerk, Darío de Jesús Mejía.
From reading these documents it is clear that the problem of housing is a ghost that has haunted Saludcoop always to the point that has led to its president, Carlos Palacino, making anxious calls for help to seek new resources.
The test is an email dated August 31, 2007. Saludcoop President after receiving a report that cash requirements by August this year were 77 billion pesos, tells the Legal Secretary, Vice President Scientific, the Regional Manager in Ontario and the Rector's Gym Pines: "As can observe is urgent to achieve revenue and reduce costs ... which proposals have "....
But these emails also expose Saludcoop strategies to try to fool the judges and more care to avoid failures Onore, the presumed existence of parallel databases, and the alleged existence of multiafiliaciones of users to the ARS.
test Disappearance
August 2010 Saludcoop president and his closest collaborators group and sensed they were being monitored by the authorities.
Monday August 9, 2010. In a conversation on Messenger that does not exceed the minute, the president and his legal secretary Saludcoop confess what will be the strategy to defend:
11:13 ... Carlos Gustavo: Darius has the text sent to us duty on the counter (it is believed that the counter is the Comptroller).
11:14 ... Darío Mejía: No doctor as I said I destroyed and erased any record.
This email had close ties with the envoy on March 6, 2011 by Carlos Palacino his legal secretary and Alejandra Benitez, manager of Processes and Transactions Ltd. E, who knew RCN Radio, reads: "I would like to inform me how you work with Everardo."
Judicial Police that analyzes the text of this e believe the man to whom they refer is the attorney Everardo Mora Poveda, who worked in the Comptroller's delegate for the Social Sector. In addition to this are the various communications that refer to Everardo Saludcoop would work with to address the investigations being conducted by the Comptroller General of the Republic, Sandra Morelli.
New Business
The emails also reveal that the president was concerned Saludcoop way to introduce new business partners from the EPS. In a Messenger conversation again with his legal secretary, Dario Mejia, and regional manager of Cundinamarca, Maria Carolina Lamus, asks for help to ensure that approve the business partners with a new clinic.
"Could you please help me draft a comprehensive agreement between what would be the new IPS - the new clinic, and the EPS for the issue of keeping the integration of processes and policies. This document must discuss it with partners before the assembly. "
Researchers evaluate whether what Saludcoop President cared about was that the new business would violate the 30% cap to engage with their own clinics or if I needed was present as another successes commissioning of the construction of the clinic La Castellana, a work that the March 13, 2011 was virtually paralyzed, with the aggravating for EPS of the Bank Colpatria required the signing of new commitments and guarantees.
to this is the controversy over the construction of an ambitious three-tower business center in the middle of Highway 108 North ... Parallel is a business that Saludcoop has invested hundreds of millions. The work has been surrounded by a number of signs as the illegal occupation of foreign lands and jockeying for the legalization and implementation of the project.
Information Management
Another point of concern to researchers is the president of Saludcoop interest in becoming an operator of the battery, which is the Form Integrated Payment of contributions.
On 14 January 2011, recently passed a health reform, Carlos Palacino asks his law clerk: "Dario: I could report that must be done to create an operator stack? ". He replied: Dr and send you the information preliminary. We are confirming with the Ministry of Social Protection for the approval process. "
On this point, say researchers and experts who know the health issue that Charles Hall is a man obsessed with controlling all the information and the possibility to be the operator of the return would give more power . Palacino is even said that aspires to win the call from Bogota to manage the database of medical records of the District.
failure handling guardianship
Saludcoop intercepted communications expose the strategy of legal secretary, Dario Mejia, to fool the judges and get protection faults do not prove even more costly to the EPS.
In an email to all the legal offices of Saludcoop, Mejia instructed in how to be oriented responses to the complaints that patients are judicially.
"Those claims must be made so that the judge did not bother to play that is taking over importance to recapture the rights of users. "
He adds that "the cost of making the first delivery to the user without further clarification has been made of the failure, is a minimal cost compared to the possible need for life cover these supplies and no chance of recovery. "
Other communication found in the legal secretary's computer recognizes that the EPS Saludcoop lying to judges and that the compliments are fictional system of sentences.
"Many answers will come by to risk (belated) by: the excessive and growing volume of cases, compliance or late deliveries, partial or staggered or charges of" compliance dummy "drug delivery is charged when the ruling ordering a wheelchair. "
multiafiliados and parallel network users
Two emails recently gained notoriety for its content, after the National Police director Gen. Oscar Naranjo, revealed the existence of maneuvers Fraudulent bases of the ARS.
In the first post compensation analyst Saludcoop, Cesar Castro, announced to the National Compensation collection and delivery of some files on multiafiliación ARS wings.
The document is dated May 18, 2007 and reads: "These are the files to deliver to the coordination of production of the EPS on the issue of the ARS multiafiliados users."
The response to this request comes four days after and researchers is equally worrisome because of its content is the impression that apparently Saludcoop manages two information systems, one public and one hidden. Martha Lucia Grosso Area Medical officer tells another: "Nancy porfa see if you can get the clone, but Eduardo engineer who works in dwh us with that."
These are some of the documents that researchers analyze Saludcoop elites search block. The others who also met the exclusive RCN Radio are draft business in Colombia and abroad, specifically in Ecuador, Chile, Panama and Dominican, and the creation of a number of companies in Colombia.
http://www.rcnradio.com/noticias/los-correos-de-saludcoop/20-05-11 
The Saludcoop Post
By: Sonia Rodriguez
Hundreds of documents, emails, conversations and telephone conversations Menssenger are part of the investigation that the search block carousel has on Saludcoop health.
RCN Radio met more than a hundred submissions that are reviewed by experts in accounting, economics, finance, international banking and healthcare.
Among the documents are e-mails between Saludcoop president, Carlos Palacino, and his closest collaborators, especially his law clerk, Darío de Jesús Mejía.
From reading these documents it is clear that the problem of housing is a ghost that has haunted Saludcoop always to the point that has led to its president, Carlos Palacino, making anxious calls for help to seek new resources.
The test is an email dated August 31, 2007. Saludcoop President after receiving a report that cash requirements by August this year were 77 billion pesos, tells the Legal Secretary, Vice President Scientific, the Regional Manager in Ontario and the Rector's Gym Pines: "As can observe is urgent to achieve revenue and reduce costs ... which proposals have "....
But these emails also expose Saludcoop strategies to try to fool the judges and more care to avoid failures Onore, the presumed existence of parallel databases, and the alleged existence of multiafiliaciones of users to the ARS.
test Disappearance
August 2010 Saludcoop president and his closest collaborators group and sensed they were being monitored by the authorities.
Monday August 9, 2010. In a conversation on Messenger that does not exceed the minute, the president and his legal secretary Saludcoop confess what will be the strategy to defend:
11:13 ... Carlos Gustavo: Darius has the text sent to us duty on the counter (it is believed that the counter is the Comptroller).
11:14 ... Darío Mejía: No doctor as I said I destroyed and erased any record.
This email had close ties with the envoy on March 6, 2011 by Carlos Palacino his legal secretary and Alejandra Benitez, manager of Processes and Transactions Ltd. E, who knew RCN Radio, reads: "I would like to inform me how you work with Everardo."
Judicial Police that analyzes the text of this e believe the man to whom they refer is the attorney Everardo Mora Poveda, who worked in the Comptroller's delegate for the Social Sector. In addition to this are the various communications that refer to Everardo Saludcoop would work with to address the investigations being conducted by the Comptroller General of the Republic, Sandra Morelli.
New Business
The emails also reveal that the president was concerned Saludcoop way to introduce new business partners from the EPS. In a Messenger conversation again with his legal secretary, Dario Mejia, and regional manager of Cundinamarca, Maria Carolina Lamus, asks for help to ensure that approve the business partners with a new clinic.
"Could you please help me draft a comprehensive agreement between what would be the new IPS - the new clinic, and the EPS for the issue of keeping the integration of processes and policies. This document must discuss it with partners before the assembly. "
Researchers evaluate whether what Saludcoop President cared about was that the new business would violate the 30% cap to engage with their own clinics or if I needed was present as another successes commissioning of the construction of the clinic La Castellana, a work that the March 13, 2011 was virtually paralyzed, with the aggravating for EPS of the Bank Colpatria required the signing of new commitments and guarantees.
to this is the controversy over the construction of an ambitious three-tower business center in the middle of Highway 108 North ... Parallel is a business that Saludcoop has invested hundreds of millions. The work has been surrounded by a number of signs as the illegal occupation of foreign lands and jockeying for the legalization and implementation of the project.
Information Management
Another point of concern to researchers is the president of Saludcoop interest in becoming an operator of the battery, which is the Form Integrated Payment of contributions.
On 14 January 2011, recently passed a health reform, Carlos Palacino asks his law clerk: "Dario: I could report that must be done to create an operator stack? ". He replied: Dr and send you the information preliminary. We are confirming with the Ministry of Social Protection for the approval process. "
On this point, say researchers and experts who know the health issue that Charles Hall is a man obsessed with controlling all the information and the possibility to be the operator of the return would give more power . Palacino is even said that aspires to win the call from Bogota to manage the database of medical records of the District.
failure handling guardianship
Saludcoop intercepted communications expose the strategy of legal secretary, Dario Mejia, to fool the judges and get protection faults do not prove even more costly to the EPS.
In an email to all the legal offices of Saludcoop, Mejia instructed in how to be oriented responses to the complaints that patients are judicially.
"Those claims must be made so that the judge did not bother to play that is taking over importance to recapture the rights of users. "
He adds that "the cost of making the first delivery to the user without further clarification has been made of the failure, is a minimal cost compared to the possible need for life cover these supplies and no chance of recovery. "
Other communication found in the legal secretary's computer recognizes that the EPS Saludcoop lying to judges and that the compliments are fictional system of sentences.
"Many answers will come by to risk (belated) by: the excessive and growing volume of cases, compliance or late deliveries, partial or staggered or charges of" compliance dummy "drug delivery is charged when the ruling ordering a wheelchair. "
multiafiliados and parallel network users
Two emails recently gained notoriety for its content, after the National Police director Gen. Oscar Naranjo, revealed the existence of maneuvers Fraudulent bases of the ARS.
In the first post compensation analyst Saludcoop, Cesar Castro, announced to the National Compensation collection and delivery of some files on multiafiliación ARS wings.
The document is dated May 18, 2007 and reads: "These are the files to deliver to the coordination of production of the EPS on the issue of the ARS multiafiliados users."
The response to this request comes four days after and researchers is equally worrisome because of its content is the impression that apparently Saludcoop manages two information systems, one public and one hidden. Martha Lucia Grosso Area Medical officer tells another: "Nancy porfa see if you can get the clone, but Eduardo engineer who works in dwh us with that."
These are some of the documents that researchers analyze Saludcoop elites search block. The others who also met the exclusive RCN Radio are draft business in Colombia and abroad, specifically in Ecuador, Chile, Panama and Dominican, and the creation of a number of companies in Colombia.
http://www.rcnradio.com/noticias/los-correos-de-saludcoop/20-05-11
Friday, May 20, 2011
Early Pregnancy With Watery Cervical Mucus
Agreal - Neurologists REMOVED-WE RULE THE FOLLOWING .....
Print
Ladies in another forum on Agreal, we have seen a comment about this medicine.
you only desire to point fighters "who Pharmacovigilance of Ministry of Health was aware of the many side effects that occurred in women taking this medication and that he retired neurologist, identifies the notification since 1995.
-------------------
THANKS DOCTOR.
THIS ASSOCIATION-L-UCHADORA AGREE, WE HAVE AT OUR DISPOSAL "YELLOW CARDS VARIOUS ADVERSE REACTIONS OF THE YEAR 1995."
BUT ALSO AND SO WE HAVE DONE IS TO KNOW THE MINISTRY OF HEALTH "NOTICES TO HAVE EVEN FROM 1989 TO 2006" -
DOCTOR AGAIN THANK YOU VERY MUCH. 
Ladies in another forum on Agreal, we have seen a comment about this medicine.
you only desire to point fighters "who Pharmacovigilance of Ministry of Health was aware of the many side effects that occurred in women taking this medication and that he retired neurologist, identifies the notification since 1995.
-------------------
THANKS DOCTOR.
THIS ASSOCIATION-L-UCHADORA AGREE, WE HAVE AT OUR DISPOSAL "YELLOW CARDS VARIOUS ADVERSE REACTIONS OF THE YEAR 1995."
BUT ALSO AND SO WE HAVE DONE IS TO KNOW THE MINISTRY OF HEALTH "NOTICES TO HAVE EVEN FROM 1989 TO 2006" -
DOCTOR AGAIN THANK YOU VERY MUCH.
Denise Milani In Toples
Conflicts of interest in the European Medicines Agency
Print
Conflicts of interest in the European Medicines Agency.
On 17 May, the electronic journal EUobserver reported that the European parliament decided almost unanimously not to approve the accounts of the European Medicines Agency (EMA) on grounds of conflict of interest and lack of transparency ( euobserver.com ). In a statement the Parliament expresses its concern "because we can not guarantee the independence of the experts" involved in the evaluation of drugs ( BMJ 2011; 342: d3081 ).
the EMA in the past had been criticized from various quarters, lack of transparency. The French journal Prescrire complained to the Ombudsman in which he complained repeatedly that the EMA had delivered records and other information on drugs with an unfavorable risk-benefit balance, such as rimonabant, telithromycin, memantine, ivabradine, telbivudine , dextropropoxyphene and ketoprofen (Rev Prescrire ).
's reputation for independence and objectivity of the EMA has been questioned after Parliament ordered an investigation into their funding sources, which come in 80% of the pharmaceutical industry. A few days earlier, the EMA had been accused of withholding information about a clinical trial by doctors at the Nordic Cochrane Centre.
In late 2010, the EMA had announced that this year would take effect more stringent rules in their relations with the pharmaceutical industry experts in order to avoid the influence of commercial interests in their decisions (BMJ 2010; 341:855 ).
Conflicts of interest may bias decisions and lead to regulatory approval drugs of doubtful efficacy or toxicity is not known. According to the EUobserver, late withdrawals benfluorex ( Mediator ) and rimonabant have endangered the health of citizens. The lack of transparency of the regulatory agencies and the protection of commercial interests can seriously affect public health.
http://w3.icf.uab.es/notibg/index.php/item/1092
Conflicts of interest in the European Medicines Agency.
On 17 May, the electronic journal EUobserver reported that the European parliament decided almost unanimously not to approve the accounts of the European Medicines Agency (EMA) on grounds of conflict of interest and lack of transparency ( euobserver.com ). In a statement the Parliament expresses its concern "because we can not guarantee the independence of the experts" involved in the evaluation of drugs ( BMJ 2011; 342: d3081 ).
the EMA in the past had been criticized from various quarters, lack of transparency. The French journal Prescrire complained to the Ombudsman in which he complained repeatedly that the EMA had delivered records and other information on drugs with an unfavorable risk-benefit balance, such as rimonabant, telithromycin, memantine, ivabradine, telbivudine , dextropropoxyphene and ketoprofen (Rev Prescrire ).
's reputation for independence and objectivity of the EMA has been questioned after Parliament ordered an investigation into their funding sources, which come in 80% of the pharmaceutical industry. A few days earlier, the EMA had been accused of withholding information about a clinical trial by doctors at the Nordic Cochrane Centre.
In late 2010, the EMA had announced that this year would take effect more stringent rules in their relations with the pharmaceutical industry experts in order to avoid the influence of commercial interests in their decisions (BMJ 2010; 341:855 ).
Conflicts of interest may bias decisions and lead to regulatory approval drugs of doubtful efficacy or toxicity is not known. According to the EUobserver, late withdrawals benfluorex ( Mediator ) and rimonabant have endangered the health of citizens. The lack of transparency of the regulatory agencies and the protection of commercial interests can seriously affect public health.
http://w3.icf.uab.es/notibg/index.php/item/1092
Power Steering Pump For 1999 Silverado
Spain develops an application to exchange information on counterfeit drugs with Latin American countries
Print
Spain develops an application to exchange information on counterfeit drugs with Latin American countries
MAST SUPERVISION
.. MADRID, 20 (EUROPA PRESS)
The English Agency for Medicines and Medical Devices (Competent Authority) under the Ministry of Health, Social Policy and Equality, has developed in recent months, a software application to improve the exchange of information on counterfeit drugs with Latin American countries.
So
reported following the last meeting of the Meetings of Competent Authorities for Medicinal Products for Latin American Countries (MAST), held from 9 to 13 May in Cartagena de Indias (Colombia), in which representatives of Ecuador, Argentina, Mexico, Guatemala, Honduras, Bolivia, Peru, Paraguay, El Salvador, Venezuela, Panama, Colombia and Spain.
This application was developed under the supervision of the Secretariat of the MAST, and accomplishes the goal of "creating a system to join efforts and to facilitate international cooperation."
Also in this meeting have agreed to implement a procedure for the management of alerts detected illegal drugs both inside and outside of legal channels for marketing and distribution.
have also highlighted the need to implement a system of rapid exchange of information to facilitate notification of each case and the development of coordinated actions between the regulatory agencies of individual member countries of the MAST.
Countries participating in this institution defend the prevention and fight against drugs illegal in each of the member countries for what they want to strengthen national systems through close collaboration between them within the MAST, so you can use to make better use of this early warning system.
In this regard, intend to establish a monitoring system that allows better management of each of the warnings issued and to assist, where possible, to elucidate in detail the characteristics of each case detected for better coordination of actions.
The MAST whose mission is to promote the exchange of technical information organizational and actual experience of its implementation among member countries to ensure access to medicines and health products, ensuring quality, efficacy and safety of themselves, from the particular focus of Latin American countries.
http://es.noticias.yahoo.com/espa% C3% B1a-develop-application% C3% B3n-exchange-information% C3% B3n-drug-false-pa% C3% ADses-122 534 781 . html
-------------------------------------
WHY NOT SHOW THEM TO MEXICO TO THE veralipride / veralipride, has been withdrawn @ OF EUROPE AND MOST LATIN AMERICAN COUNTRIES, BY THE "TERRIBLE AND IRREVERSIBLE DAMAGE TO PRODUCE THE LIFETIME ACLIMAFEL / veralipride?.
Spain develops an application to exchange information on counterfeit drugs with Latin American countries
MAST SUPERVISION
.. MADRID, 20 (EUROPA PRESS)
The English Agency for Medicines and Medical Devices (Competent Authority) under the Ministry of Health, Social Policy and Equality, has developed in recent months, a software application to improve the exchange of information on counterfeit drugs with Latin American countries.
So
reported following the last meeting of the Meetings of Competent Authorities for Medicinal Products for Latin American Countries (MAST), held from 9 to 13 May in Cartagena de Indias (Colombia), in which representatives of Ecuador, Argentina, Mexico, Guatemala, Honduras, Bolivia, Peru, Paraguay, El Salvador, Venezuela, Panama, Colombia and Spain.
This application was developed under the supervision of the Secretariat of the MAST, and accomplishes the goal of "creating a system to join efforts and to facilitate international cooperation."
Also in this meeting have agreed to implement a procedure for the management of alerts detected illegal drugs both inside and outside of legal channels for marketing and distribution.
have also highlighted the need to implement a system of rapid exchange of information to facilitate notification of each case and the development of coordinated actions between the regulatory agencies of individual member countries of the MAST.
Countries participating in this institution defend the prevention and fight against drugs illegal in each of the member countries for what they want to strengthen national systems through close collaboration between them within the MAST, so you can use to make better use of this early warning system.
In this regard, intend to establish a monitoring system that allows better management of each of the warnings issued and to assist, where possible, to elucidate in detail the characteristics of each case detected for better coordination of actions.
The MAST whose mission is to promote the exchange of technical information organizational and actual experience of its implementation among member countries to ensure access to medicines and health products, ensuring quality, efficacy and safety of themselves, from the particular focus of Latin American countries.
http://es.noticias.yahoo.com/espa% C3% B1a-develop-application% C3% B3n-exchange-information% C3% B3n-drug-false-pa% C3% ADses-122 534 781 . html
-------------------------------------
WHY NOT SHOW THEM TO MEXICO TO THE veralipride / veralipride, has been withdrawn @ OF EUROPE AND MOST LATIN AMERICAN COUNTRIES, BY THE "TERRIBLE AND IRREVERSIBLE DAMAGE TO PRODUCE THE LIFETIME ACLIMAFEL / veralipride?.
Bath Mat Wihtout Suction Cups
something fa a les grans FERUM farmacèutiques Drug companies spend almost
Print
drugs are the third world economic activity after the arms trade and drug trafficking ...
in Spain Drugmakers spend more than 2,500 million euros in promoting , ie for purchasing decisions: almost three times the money on research ...
In EE. UU. the side effects of medications are the fourth leading cause of death, ahead of diabetes, COPD (chronic obstructive pulmonary disease) and traffic accidents. In the FICF estimate that every year in Spain tens of thousands of people by those side effects ...
Medical Laboratory (ed. Peninsula), Miguel Jara, collect illegal practices to ensure that a particular drug médicosreceten recommended by health visitors.
Gods in white coats (Ed. Planeta), Josep Ramon Germà Lluch, facing the vanity and the desire of the éticamédicade éxitoa two oncologists at the trial of a drug.
match Two books now in bookstores, an essay and a novel, to bring his vision about the intricacies of this sector. Medical Laboratory, Miguel Jara (Peninsula), in his essay proposes a journey inside medicine and the pharmaceutical industry through the health visitor, a figure disputed in this work by promoting business cases, lucrative for your business but sometimes at the expense of the interests of the patient. This is the game of Jara thesis: most laboratories pursue the profitability of their medications but sometimes it involves ignoring the rights of citizens.
Miguel Jara, writer and journalist, a researcher in health and ecology, a former correspondent in Spain of the British Medical Journal, has heard dozens of stories of visitors who say they are kidnapped by their work. Laboratories to put pressure on doctors to prescribe their products through their sales teams is something that few others see legend and reality. When the case of "institutionalized form," insists the author, citizenship can expect to pay a toll of health, deteriorates the prestige of medicine, and is a fraud on the public finances.
Since 2002, the relationship between pharmaceutical companies and physicians is regulated by a Code of Practice. And the industry defends him: "This code was provided with the resulting self-regulation, whose breach entails serious economic penalties for companies filed," said Julian Zabala, director of communications Farmaindustria.
The situation began to change a decade ago. "Scientific societies are much more vigilant when a specialist participates in an investigation prompted declaration of conflict of interest," said Dr. James Sellarés, board member of the College of Metges of Barcelona. "We can not ensure that there are these bad practices, but not like before. It is a model of the last century, which left the Administration in the hands of industry training for doctors."
And with economic cutbacks, the industry has fewer resources to invest in physicians. "Now many do not accept input CAP of visitors. "Sellarés says.
The novel which exposes the murky machinations of the pharmaceutical industry is the subtitle that Metro has been used as bait to morbid for Gods in white coats, fiction has Wrote oncologist Barcelona, \u200b\u200bJosep Ramon Germà Lluch, director of knowledge management and department head of Medical Oncology at the Institut Català d'Oncologia (ICO). It is part of the world of clinical trials, the desire for success and hurry to do so. The central scenario is Barcelona and their oncologists star.
"I had the need for it is possible to report when things are not done right," says the author. Again according to his thesis, the rush has led to the occurrence of deaths from long-term effects of drugs that had not been sufficiently studied. "The story is based on real events, but set in the field of oncology, because it is what I know best, not because he is telling something that happened with drugs for cancer," he says.
Germà Lluch about drug recalls in history were more or less recent hugely damaging for various failures during the investigation and that are now banned and withdrawn. As a drug, thalidomide, for nausea during pregnancy, depending on when he took caused serious injuries to the fetus. O estrogen for menopause, which if taken for more than five years increased the incidence of breast cancer. Always using that game between reality and fiction, Lluch recalls heart problems that gave an antidiabetic retired just two years ago in France.
"The rush and pressure us to lose critical," said Lluch. This shortcoming and the huge amount of money is at stake, "we do sometimes lose sight of why things are done." In the novel tells a world of clinical trials almost chain through effective external companies themselves coldly laboratories that meet the test objective, regardless of their impact. A world of healing measured in many zeros. Fact or fiction, asks the reader. "Taking a drug can cost 1,700 million dollars and it takes 12 or 14 years. Now you try it in 7 or 8. It may be little time to see what the long-term effects."
The two big agencies that allow drugs (The U.S. FDA and European EMA) are the same institutions that have to withdraw a drug when it goes well, says the oncologist. And besides, the industry can pay to have the review process be shortened. "We still critical - .Necesitamos adds more than ever, discussion groups on the clinical benefit that should have at least one drug."
Meanwhile, questions remain about the functioning of the European Medicines Agency. For many MEPs, the agency responsible for ensuring their safety, is very sensitive to the interests of big pharma and last week the Parliament not only refused to endorse their accounts of the past two years but ordered the opening of an investigation into the source of their funding, Beatriz Navarro reports. "There is no guarantee that the development of medicines is carried out by independent experts," says the European Parliament, warning of possible "conflict of interest" in the Agency. MEPs question the actions of the Agency in the case of a drug to treat diabetes (benflourex before sold as Mediator), which took 10 years off the market since the first reports warning of dangerous side effects. The agency has been accused of lacking transparency. It took a decision of the Ombudsman for the Agency agreed to publish reports on clinical trials held in secret on the grounds of not harming the interests of manufacturers.
In an article published on 11 in the British Medical Journal, doctors Danish Anders Peter Gøtzschey Jørgensenculpan to the European Medicines Agency (EMEA) of having "the profits of drug companies above the protection of life and welfare of the patient. " In particular, complain of "selective publication" of the tests performed on drugs. This practice, they say, is "widespread" leads to "overstate the benefits and underestimate the damage" from the drug, which makes that "doctors can not choose the best treatment for our patients." Jørgensen Gøtzschey highlights "disastrous consequences" that it may have, as was seen with the painkiller rofecoxib, "which may have caused 100,000 heart attacks unnecessary EE. UU.." These physicians reported that it took more than three years to ensure that the EMP will provide the evidence published on the anti-obesity drug Rimonabant, in 2010, was withdrawn because of side effects.
Something smells rotten " in the pharmaceutical sector, claimed three years ago the then European Commissioner for Competition, Neelie Kroes from the Netherlands. His services had detected the presence of suspicious business practices stop trying to market the generic drug, depriving European public health substantial savings. On average, these products are 40% cheaper than original drugs.
Large pharmaceutical companies are suspect for example, to launch complex legal proceedings to postpone the launch of generics, making multiple records for the same medicine, patent intermediates for their production and also difficult to "buy" to generic manufacturers to remove them as long as possible market.
seems harsh words Kroes (and its threat to impose substantial fines) took effect, because only a year and a half after the European Commission found a substantial reduction in the number of agreements concluded between companies suspected sector. Between 2000 and 2008, 22% of the Covenants killings between big pharma and generic manufacturers raised concerns, versus 10% of cases closed in the first half of 2008.
However, Brussels does not lower his guard and keeps these companies in check. Before the summer will publish its second report on the developments. "There is still concern," EU sources say . The proof is in the three cases opened in recent months companies suspected of trying to stop the sale of generic equivalents Citalopram, a popular antidepressant, or to Modafinil, used to treat sleep disorders. The threat of fines from the EU remains on the table.
17-V-11, N. Escur / A. MacPherson / B. Navarro, bbc
http://www.barcelonaradical.net/informacion.php?iinfo=22249 
drugs are the third world economic activity after the arms trade and drug trafficking ...
in Spain Drugmakers spend more than 2,500 million euros in promoting , ie for purchasing decisions: almost three times the money on research ...
In EE. UU. the side effects of medications are the fourth leading cause of death, ahead of diabetes, COPD (chronic obstructive pulmonary disease) and traffic accidents. In the FICF estimate that every year in Spain tens of thousands of people by those side effects ...
Medical Laboratory (ed. Peninsula), Miguel Jara, collect illegal practices to ensure that a particular drug médicosreceten recommended by health visitors.
Gods in white coats (Ed. Planeta), Josep Ramon Germà Lluch, facing the vanity and the desire of the éticamédicade éxitoa two oncologists at the trial of a drug.
match Two books now in bookstores, an essay and a novel, to bring his vision about the intricacies of this sector. Medical Laboratory, Miguel Jara (Peninsula), in his essay proposes a journey inside medicine and the pharmaceutical industry through the health visitor, a figure disputed in this work by promoting business cases, lucrative for your business but sometimes at the expense of the interests of the patient. This is the game of Jara thesis: most laboratories pursue the profitability of their medications but sometimes it involves ignoring the rights of citizens.
Miguel Jara, writer and journalist, a researcher in health and ecology, a former correspondent in Spain of the British Medical Journal, has heard dozens of stories of visitors who say they are kidnapped by their work. Laboratories to put pressure on doctors to prescribe their products through their sales teams is something that few others see legend and reality. When the case of "institutionalized form," insists the author, citizenship can expect to pay a toll of health, deteriorates the prestige of medicine, and is a fraud on the public finances.
Since 2002, the relationship between pharmaceutical companies and physicians is regulated by a Code of Practice. And the industry defends him: "This code was provided with the resulting self-regulation, whose breach entails serious economic penalties for companies filed," said Julian Zabala, director of communications Farmaindustria.
The situation began to change a decade ago. "Scientific societies are much more vigilant when a specialist participates in an investigation prompted declaration of conflict of interest," said Dr. James Sellarés, board member of the College of Metges of Barcelona. "We can not ensure that there are these bad practices, but not like before. It is a model of the last century, which left the Administration in the hands of industry training for doctors."
And with economic cutbacks, the industry has fewer resources to invest in physicians. "Now many do not accept input CAP of visitors. "Sellarés says.
The novel which exposes the murky machinations of the pharmaceutical industry is the subtitle that Metro has been used as bait to morbid for Gods in white coats, fiction has Wrote oncologist Barcelona, \u200b\u200bJosep Ramon Germà Lluch, director of knowledge management and department head of Medical Oncology at the Institut Català d'Oncologia (ICO). It is part of the world of clinical trials, the desire for success and hurry to do so. The central scenario is Barcelona and their oncologists star.
"I had the need for it is possible to report when things are not done right," says the author. Again according to his thesis, the rush has led to the occurrence of deaths from long-term effects of drugs that had not been sufficiently studied. "The story is based on real events, but set in the field of oncology, because it is what I know best, not because he is telling something that happened with drugs for cancer," he says.
Germà Lluch about drug recalls in history were more or less recent hugely damaging for various failures during the investigation and that are now banned and withdrawn. As a drug, thalidomide, for nausea during pregnancy, depending on when he took caused serious injuries to the fetus. O estrogen for menopause, which if taken for more than five years increased the incidence of breast cancer. Always using that game between reality and fiction, Lluch recalls heart problems that gave an antidiabetic retired just two years ago in France.
"The rush and pressure us to lose critical," said Lluch. This shortcoming and the huge amount of money is at stake, "we do sometimes lose sight of why things are done." In the novel tells a world of clinical trials almost chain through effective external companies themselves coldly laboratories that meet the test objective, regardless of their impact. A world of healing measured in many zeros. Fact or fiction, asks the reader. "Taking a drug can cost 1,700 million dollars and it takes 12 or 14 years. Now you try it in 7 or 8. It may be little time to see what the long-term effects."
The two big agencies that allow drugs (The U.S. FDA and European EMA) are the same institutions that have to withdraw a drug when it goes well, says the oncologist. And besides, the industry can pay to have the review process be shortened. "We still critical - .Necesitamos adds more than ever, discussion groups on the clinical benefit that should have at least one drug."
Meanwhile, questions remain about the functioning of the European Medicines Agency. For many MEPs, the agency responsible for ensuring their safety, is very sensitive to the interests of big pharma and last week the Parliament not only refused to endorse their accounts of the past two years but ordered the opening of an investigation into the source of their funding, Beatriz Navarro reports. "There is no guarantee that the development of medicines is carried out by independent experts," says the European Parliament, warning of possible "conflict of interest" in the Agency. MEPs question the actions of the Agency in the case of a drug to treat diabetes (benflourex before sold as Mediator), which took 10 years off the market since the first reports warning of dangerous side effects. The agency has been accused of lacking transparency. It took a decision of the Ombudsman for the Agency agreed to publish reports on clinical trials held in secret on the grounds of not harming the interests of manufacturers.
In an article published on 11 in the British Medical Journal, doctors Danish Anders Peter Gøtzschey Jørgensenculpan to the European Medicines Agency (EMEA) of having "the profits of drug companies above the protection of life and welfare of the patient. " In particular, complain of "selective publication" of the tests performed on drugs. This practice, they say, is "widespread" leads to "overstate the benefits and underestimate the damage" from the drug, which makes that "doctors can not choose the best treatment for our patients." Jørgensen Gøtzschey highlights "disastrous consequences" that it may have, as was seen with the painkiller rofecoxib, "which may have caused 100,000 heart attacks unnecessary EE. UU.." These physicians reported that it took more than three years to ensure that the EMP will provide the evidence published on the anti-obesity drug Rimonabant, in 2010, was withdrawn because of side effects.
Something smells rotten " in the pharmaceutical sector, claimed three years ago the then European Commissioner for Competition, Neelie Kroes from the Netherlands. His services had detected the presence of suspicious business practices stop trying to market the generic drug, depriving European public health substantial savings. On average, these products are 40% cheaper than original drugs.
Large pharmaceutical companies are suspect for example, to launch complex legal proceedings to postpone the launch of generics, making multiple records for the same medicine, patent intermediates for their production and also difficult to "buy" to generic manufacturers to remove them as long as possible market.
seems harsh words Kroes (and its threat to impose substantial fines) took effect, because only a year and a half after the European Commission found a substantial reduction in the number of agreements concluded between companies suspected sector. Between 2000 and 2008, 22% of the Covenants killings between big pharma and generic manufacturers raised concerns, versus 10% of cases closed in the first half of 2008.
However, Brussels does not lower his guard and keeps these companies in check. Before the summer will publish its second report on the developments. "There is still concern," EU sources say . The proof is in the three cases opened in recent months companies suspected of trying to stop the sale of generic equivalents Citalopram, a popular antidepressant, or to Modafinil, used to treat sleep disorders. The threat of fines from the EU remains on the table.
17-V-11, N. Escur / A. MacPherson / B. Navarro, bbc
http://www.barcelonaradical.net/informacion.php?iinfo=22249
Watch Movie Gundam Seed
three times on promotion than on research
Print
By Rafael Vilalta, May 17th, 2011
A sales representative's visit generates about 35 new prescriptions of the drug, says Professor Joan-Ramon Laporte, head of the pharmacology of the Vall d'Hebron Hospital and director of the Fundació Institut Català of Pharmacology (WHO collaborating).
Do you understand that there are citizens who are suspicious of pharmaceutical companies?
Yes companies exaggerate the benefits of the drugs they sell, and minimize or even deny, the effects serious side. For citizens, are a tool for health. For pharmaceuticals, are a product to sell to the fullest.
Is there enough control in the sector?
Rather, they are the pharmaceutical companies that control to the states, and not vice versa, it should be. More than an insufficient legal regulation, a set of laws and regulations designed to encourage pharmaceutical companies. Buy pharmaceutical lobbies politicians, regulators, health professionals and patient associations.
And in the U.S.?
In the U.S. spend more than $ 500 million annually in lobbying (which are legal) on politicians to change laws or proposed legislation, it is estimated that there are eight or nine pressured ( English, lobbyists) for each congressman. Drugs are the third world economic activity after the arms trade and drug trafficking.
What solution is to cases of medical representatives who buy prescriptions?
has been and is still going on more or less formal purchase, gifts, meals, travel ... Many doctors accept it thinking that it influences their decisions to prescribe a drug or another. Pharmaceutical companies in Spain spent more than 2,500 million euros on promotion, that is, purchasing decisions, nearly triple the money in research.
If you are doing, is it because they find it profitable?
Yes No employer in their right mind would enter in your company representatives of other companies from raw materials to make there market its products. But in health centers is done.
The European Medicines Agency estimated that in Europe die each year 197,000 people due to adverse effects of medicines.
The figure is probably underreported. U.S. the side effects of medications are the fourth leading cause of death, ahead of diabetes, COPD (chronic obstructive pulmonary disease) and traffic accidents. In the FICF estimate that every year in Spain, tens of thousands of people for these unwanted effects.
What worries you most?
That the authorities do not worry about knowing what positive and negative effects of the drugs. They see the price, but not the effects.
http://www.pharmanetworkingspain.com/noticias/laporte-los-laboratorios-gastan-casi-el-triple-en-promocion-que-en-investigacion/ 
By Rafael Vilalta, May 17th, 2011
A sales representative's visit generates about 35 new prescriptions of the drug, says Professor Joan-Ramon Laporte, head of the pharmacology of the Vall d'Hebron Hospital and director of the Fundació Institut Català of Pharmacology (WHO collaborating).
Do you understand that there are citizens who are suspicious of pharmaceutical companies?
Yes companies exaggerate the benefits of the drugs they sell, and minimize or even deny, the effects serious side. For citizens, are a tool for health. For pharmaceuticals, are a product to sell to the fullest.
Is there enough control in the sector?
Rather, they are the pharmaceutical companies that control to the states, and not vice versa, it should be. More than an insufficient legal regulation, a set of laws and regulations designed to encourage pharmaceutical companies. Buy pharmaceutical lobbies politicians, regulators, health professionals and patient associations.
And in the U.S.?
In the U.S. spend more than $ 500 million annually in lobbying (which are legal) on politicians to change laws or proposed legislation, it is estimated that there are eight or nine pressured ( English, lobbyists) for each congressman. Drugs are the third world economic activity after the arms trade and drug trafficking.
What solution is to cases of medical representatives who buy prescriptions?
has been and is still going on more or less formal purchase, gifts, meals, travel ... Many doctors accept it thinking that it influences their decisions to prescribe a drug or another. Pharmaceutical companies in Spain spent more than 2,500 million euros on promotion, that is, purchasing decisions, nearly triple the money in research.
If you are doing, is it because they find it profitable?
Yes No employer in their right mind would enter in your company representatives of other companies from raw materials to make there market its products. But in health centers is done.
The European Medicines Agency estimated that in Europe die each year 197,000 people due to adverse effects of medicines.
The figure is probably underreported. U.S. the side effects of medications are the fourth leading cause of death, ahead of diabetes, COPD (chronic obstructive pulmonary disease) and traffic accidents. In the FICF estimate that every year in Spain, tens of thousands of people for these unwanted effects.
What worries you most?
That the authorities do not worry about knowing what positive and negative effects of the drugs. They see the price, but not the effects.
http://www.pharmanetworkingspain.com/noticias/laporte-los-laboratorios-gastan-casi-el-triple-en-promocion-que-en-investigacion/
Hooking An External Hard Drive To Sony Tv
side effects in the treatment of pain: paracetamol
side effects in the treatment of pain: paracetamol.
The pain is present in almost all diseases, so that the drugs used to alleviate it are widely used. Different studies point to these as one of the most used therapeutic subgroups and their consumption not to be increased year after year.
From the pharmacological standpoint, analgesics and antipyretics marketed in Spain have traditionally been classified into "acetylsalicylic acid derivatives," pyrazolones "," paracetamol and derivatives "and" other pain relievers and antipyretics. Of all the analgesics mentioned ( within this subgroup include NSAIDs including ibuprofen highlights to be discussed in an article from ), few are those who represent the largest share of consumption, in particular paracetamol and to a lesser extent, metamizol. Analgesic consumption has tripled between 1992 and 2006. This increase occurred at the expense of the use of paracetamol, which has risen from 50.9% of this subgroup in 1992 to over 75% in 2006.
Eye! Acetaminophen is not as harmless as we thought.
Paracetamol is indicated for the symptomatic relief of occasional mild to moderate pain such as headache, dental, muscular (contractures) or back pain (LBP) and as an antipyretic in febrile conditions.
When compared with other drugs for these indications, has a relatively good safety profile at normal doses which allowed adoption in many prescription medicines to the public that can be taken without medical supervision.
more adverse reactions have been reported during the period use of paracetamol hepatotoxicity, renal toxicity, abnormal blood count, hypoglycemia, and allergic dermatitis.
Paracetamol should not be taken for long periods of time nor in high doses, since even at therapeutic doses do not usually have toxic effects, both at very high doses and prolonged use continuous (usually after a year, but sometimes from week 3) can cause liver toxicity.
http://es.tendencias.yahoo.com/salud/efectos-secundarios-en-el-tratamiento-del-dolor-paracetamol-article-m0da.html 
side effects in the treatment of pain: paracetamol.
The pain is present in almost all diseases, so that the drugs used to alleviate it are widely used. Different studies point to these as one of the most used therapeutic subgroups and their consumption not to be increased year after year.
Eye! Acetaminophen is not as harmless as we thought.
Paracetamol is indicated for the symptomatic relief of occasional mild to moderate pain such as headache, dental, muscular (contractures) or back pain (LBP) and as an antipyretic in febrile conditions.
When compared with other drugs for these indications, has a relatively good safety profile at normal doses which allowed adoption in many prescription medicines to the public that can be taken without medical supervision.
more adverse reactions have been reported during the period use of paracetamol hepatotoxicity, renal toxicity, abnormal blood count, hypoglycemia, and allergic dermatitis.
Paracetamol should not be taken for long periods of time nor in high doses, since even at therapeutic doses do not usually have toxic effects, both at very high doses and prolonged use continuous (usually after a year, but sometimes from week 3) can cause liver toxicity.
http://es.tendencias.yahoo.com/salud/efectos-secundarios-en-el-tratamiento-del-dolor-paracetamol-article-m0da.html
Thursday, May 19, 2011
Leather Dominatrix In Boots
As our friend "MIGUEL JARA" IN HIS BOOK "THE PRODUCE Agreal: Experts seek to standardize the approach to thyroid cancer in Spain
Print
Experts seek to homogenise the approach of thyroid cancer Spain.
The Thyroid Cancer Group of the English Society of Endocrinology and Nutrition (SEEN) is organizing, under the auspices of Genzyme, a symposium on the disease.
- The protocol continues today in our country is the best, but it was found that clinical practice is not uniform - This disease has a low but increasing incidence in the northwest English, according to an epidemiological study of 2009 conducted by the Hospital Universitario de Vigo - In areas of Galicia, where extremely low iodine intake predominantly follicular thyroid cancers, which are often particularly aggressive-Ionising radiation is the most recognized trigger of the disease and is also shown that populations near areas present volcanic prevalence ten times higher than other areas "Another of the issues addressed at the symposium has been monitoring biochemical differentiated thyroid carcinoma.
Santiago de Compostela, May 18, 2011. Differentiated thyroid cancer is the most frequent endocrine cancer, however, is rare compared with other types of cancers.
In general, the average age of diagnosis is between 40 and 53 years , being especially prevalent among white women. In order to update knowledge about its approach, the Thyroid Cancer Group of the English Society of Endocrinology and Nutrition (SEEN) has organized in the context of 53 SEEN Congress and sponsored by Genzyme, the symposium "taking a position in relation to current treatment protocols Node and differentiated thyroid cancer; Creating Multidisciplinary Committees" . has low but increasing incidence, Spain occupies an intermediate position compared with other European countries . The trend is the same in the case of northwestern English, according to an epidemiological study of 2009 conducted by the Hospital Universitario de Vigo. Of the 322 new cases registered between 1978 and 2001 in the hospital (for a stock 500,000 inhabitants), 76% were papillary thyroid cancers, with special emphasis among women . On the other hand, "in areas of Galicia where extremely low iodine intake predominantly follicular thyroid cancers, which tend to be more aggressive," said Dr. Ricardo V. García-Mayor, Chief of Endocrinology and Nutrition from General Hospital of Vigo (Pontevedra ). "Although ionizing radiation are the most recognized trigger of the disease, is also shown that populations near volcanic areas have a prevalence ten times higher than other areas, " points. Among the latest developments in the approach of differentiated thyroid cancer, the expert referred to is giving promising results using genetic techniques in the diagnosis of the disease. Also referred to the "breakthrough that has led to the staging of tumors of the face to the personalization of surgical treatment, and the establishment of different protocols depending on the forecast track," he explains. The protocol followed in Spain, the best possible.
According to Dr. José Manuel Gómez Sáez, coordinator of the Thyroid Cancer the SEEN, pointed as a major objective of the meeting "coordination of multidisciplinary approach of the nodule and differentiated thyroid cancer in Spain following the model of the European consensus attitude of thyroid cancer and American guidance, revised in November 2009 ". Given the nature of this cancer, "made necessary efforts and expertise of specialists, including an endocrinologist should be the main coordinator for who first see these patients," he explains. "The protocol that is followed today in our country is the best, but we found that the practice is not uniform ". Another of the topics discussed at the symposium was the biochemical monitoring differentiated thyroid carcinoma, which " is based on the determination of basal or stimulated thyroglobulin to recombinant human TSH, along with ultrasound and other techniques possible vertical " says Dr. Gómez Sáez. The limitation of this process is in its complexity, mainly due to the molecular structure and some analytical interferences has to be taken into account, "he says. Finally, we have pooled the new criteria of surgical treatment of this cancer and the proposals of Nuclear Medicine in the diagnosis and treatment. About Genzyme
Genzyme, one of the leading biotech companies worldwide, is focused on achieving the greatest positive impact on the lives of people affected by serious illness. Since its founding in 1981, Genzyme has developed innovative treatments in several therapeutic areas, providing new hope to patients. Today, Genzyme approximately 10,000 employees are dedicated to serving patients in nearly 100 countries. Genzyme's products are focused on rare inherited diseases, kidney disease, orthopedics, cancer, transplant and immune diseases. Our commitment to innovation continues today, with major programs focused on developing therapeutic areas mentioned, as well as cardiovascular, neurodegenerative diseases and other areas with unmet medical needs. Genzyme part of Sanofi-aventis group.
Sanofi-aventis, a leading pharmaceutical company worldwide, discovers, develops and distributes therapeutic solutions to improve the lives people . -----------------
SANOFI "IMPROVE PEOPLE'S LIVES?
he has done with women, both Europe and Latin America with its Agreal / AGRADIL / ACLIMAFEL / veralipride?
HUNDREDS AND HUNDREDS OF WOMEN WITH THYROID serious problems, REMOVAL OF LYMPH AND RETURNED TO REPRODUCIRSELES.
OTHER OF "MANY malice" HID WITH veralipride / veralipride.
HAVE "TRAFFIC AND TRAFFIC WITH THE" HEALTH OF MILLIONS OF WOMEN.
SANOFI:
"NO MORE malice" WITH "Agreal / veralipride IN SPAIN ".
http://www.acceso.com/es_ES/notas-de-prensa/expertos-buscan-homogeneizar-el-abordaje-del-cancer-de-tiroides-en-espana/75407/ 
Experts seek to homogenise the approach of thyroid cancer Spain.
The Thyroid Cancer Group of the English Society of Endocrinology and Nutrition (SEEN) is organizing, under the auspices of Genzyme, a symposium on the disease.
- The protocol continues today in our country is the best, but it was found that clinical practice is not uniform - This disease has a low but increasing incidence in the northwest English, according to an epidemiological study of 2009 conducted by the Hospital Universitario de Vigo - In areas of Galicia, where extremely low iodine intake predominantly follicular thyroid cancers, which are often particularly aggressive-Ionising radiation is the most recognized trigger of the disease and is also shown that populations near areas present volcanic prevalence ten times higher than other areas "Another of the issues addressed at the symposium has been monitoring biochemical differentiated thyroid carcinoma.
Santiago de Compostela, May 18, 2011. Differentiated thyroid cancer is the most frequent endocrine cancer, however, is rare compared with other types of cancers.
In general, the average age of diagnosis is between 40 and 53 years , being especially prevalent among white women. In order to update knowledge about its approach, the Thyroid Cancer Group of the English Society of Endocrinology and Nutrition (SEEN) has organized in the context of 53 SEEN Congress and sponsored by Genzyme, the symposium "taking a position in relation to current treatment protocols Node and differentiated thyroid cancer; Creating Multidisciplinary Committees" . has low but increasing incidence, Spain occupies an intermediate position compared with other European countries . The trend is the same in the case of northwestern English, according to an epidemiological study of 2009 conducted by the Hospital Universitario de Vigo. Of the 322 new cases registered between 1978 and 2001 in the hospital (for a stock 500,000 inhabitants), 76% were papillary thyroid cancers, with special emphasis among women . On the other hand, "in areas of Galicia where extremely low iodine intake predominantly follicular thyroid cancers, which tend to be more aggressive," said Dr. Ricardo V. García-Mayor, Chief of Endocrinology and Nutrition from General Hospital of Vigo (Pontevedra ). "Although ionizing radiation are the most recognized trigger of the disease, is also shown that populations near volcanic areas have a prevalence ten times higher than other areas, " points. Among the latest developments in the approach of differentiated thyroid cancer, the expert referred to is giving promising results using genetic techniques in the diagnosis of the disease. Also referred to the "breakthrough that has led to the staging of tumors of the face to the personalization of surgical treatment, and the establishment of different protocols depending on the forecast track," he explains. The protocol followed in Spain, the best possible.
According to Dr. José Manuel Gómez Sáez, coordinator of the Thyroid Cancer the SEEN, pointed as a major objective of the meeting "coordination of multidisciplinary approach of the nodule and differentiated thyroid cancer in Spain following the model of the European consensus attitude of thyroid cancer and American guidance, revised in November 2009 ". Given the nature of this cancer, "made necessary efforts and expertise of specialists, including an endocrinologist should be the main coordinator for who first see these patients," he explains. "The protocol that is followed today in our country is the best, but we found that the practice is not uniform ". Another of the topics discussed at the symposium was the biochemical monitoring differentiated thyroid carcinoma, which " is based on the determination of basal or stimulated thyroglobulin to recombinant human TSH, along with ultrasound and other techniques possible vertical " says Dr. Gómez Sáez. The limitation of this process is in its complexity, mainly due to the molecular structure and some analytical interferences has to be taken into account, "he says. Finally, we have pooled the new criteria of surgical treatment of this cancer and the proposals of Nuclear Medicine in the diagnosis and treatment. About Genzyme
Genzyme, one of the leading biotech companies worldwide, is focused on achieving the greatest positive impact on the lives of people affected by serious illness. Since its founding in 1981, Genzyme has developed innovative treatments in several therapeutic areas, providing new hope to patients. Today, Genzyme approximately 10,000 employees are dedicated to serving patients in nearly 100 countries. Genzyme's products are focused on rare inherited diseases, kidney disease, orthopedics, cancer, transplant and immune diseases. Our commitment to innovation continues today, with major programs focused on developing therapeutic areas mentioned, as well as cardiovascular, neurodegenerative diseases and other areas with unmet medical needs. Genzyme part of Sanofi-aventis group.
Sanofi-aventis, a leading pharmaceutical company worldwide, discovers, develops and distributes therapeutic solutions to improve the lives people . -----------------
SANOFI "IMPROVE PEOPLE'S LIVES?
he has done with women, both Europe and Latin America with its Agreal / AGRADIL / ACLIMAFEL / veralipride?
HUNDREDS AND HUNDREDS OF WOMEN WITH THYROID serious problems, REMOVAL OF LYMPH AND RETURNED TO REPRODUCIRSELES.
OTHER OF "MANY malice" HID WITH veralipride / veralipride.
HAVE "TRAFFIC AND TRAFFIC WITH THE" HEALTH OF MILLIONS OF WOMEN.
SANOFI:
"NO MORE malice" WITH "Agreal / veralipride IN SPAIN ".
http://www.acceso.com/es_ES/notas-de-prensa/expertos-buscan-homogeneizar-el-abordaje-del-cancer-de-tiroides-en-espana/75407/
Going Away Party Invitation Wording
Agreal THIS Wrestler , ME AND OFFER TO THIS NOTICE: Deep brain stimulation in the treatment of depression Revolcón
Print
deep brain stimulation to treat depression.
deep brain stimulation (DBS) is safe and effective in treatment-resistant depression (TRD) of up to 6 years, suggests new research published in the American Journal of Psychiatry .
In this study, the researchers found that patients who underwent DRT deep brain stimulation of the cingulate gyrus region had a rate subcallosa average response of 64.3% between 3 to 6 years later. And more than one third of patients were in remission at 3 years.
Although adverse events did not appear, 2 patients died by suicide during depressive outbreaks. This suggests the need Further tests with larger samples to confirm these results and also reinforces the importance of psychiatric treatment in the long term, including psychosocial and pharmacological treatments in combination with deep brain stimulation.
[Am J Psychiatry 2011]
Kennedy SH, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y, Mayberg HS, et al.
http://www.neurologia.com/sec/RSS/noticias.php?idNoticia=2837 -----------------
I do not care:
"SHOOT ME THOSE ARISING EVEN MORE Depressive. "
deep brain stimulation to treat depression.
Although adverse events did not appear, 2 patients died by suicide during depressive outbreaks. This suggests the need Further tests with larger samples to confirm these results and also reinforces the importance of psychiatric treatment in the long term, including psychosocial and pharmacological treatments in combination with deep brain stimulation.
[Am J Psychiatry 2011]
Kennedy SH, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y, Mayberg HS, et al.
http://www.neurologia.com/sec/RSS/noticias.php?idNoticia=2837 -----------------
I do not care:
Hatchet Vs Genitals -reaction
health with human papillomavirus vaccine
Print
Thursday May 19, 2011
BURGO PG OF VALENCIA
adverse reaction to the second dose of the human papillomavirus vaccine resulted in two teenagers Valencia on 14 and 15 who began to suffer seizures and were hospitalized in the ICU of the Clinical Hospital of Valencia generated a veritable wave of social rejection to the vaccination campaign, which was the first in the Region and the rest of Spain. The Ministry of Health immobilized thousands of units in the lot that had been inoculated with the girls, who went into a coma in the hospital.
One of the children lived in Burjassot and the other on the promenade. The only common element was a prick the preventive that remained hospitalized more than two months . Health failed to overcome the injury. Following the event, laboratories, scientific societies and health authorities were determined to move the population that the vaccine was beneficial but the campaign and had exploded in his hands and was recovered.
http://www.levante-emv.com/comunitat-valenciana/2011/05/19/revolcon-sanitario-vacuna-papiloma-humano/808241.html
Thursday May 19, 2011
BURGO PG OF VALENCIA
adverse reaction to the second dose of the human papillomavirus vaccine resulted in two teenagers Valencia on 14 and 15 who began to suffer seizures and were hospitalized in the ICU of the Clinical Hospital of Valencia generated a veritable wave of social rejection to the vaccination campaign, which was the first in the Region and the rest of Spain. The Ministry of Health immobilized thousands of units in the lot that had been inoculated with the girls, who went into a coma in the hospital.
One of the children lived in Burjassot and the other on the promenade. The only common element was a prick the preventive that remained hospitalized more than two months . Health failed to overcome the injury. Following the event, laboratories, scientific societies and health authorities were determined to move the population that the vaccine was beneficial but the campaign and had exploded in his hands and was recovered.
http://www.levante-emv.com/comunitat-valenciana/2011/05/19/revolcon-sanitario-vacuna-papiloma-humano/808241.html
Putting Salt On A Sebaceous Cyst
Publication Date: May 18, 2011 - OCTAGAMOCTA 50 mg / ml and 100 mg / ml:
Print
Category: DRUGS FOR HUMAN USE.
Reference: MUH, 7 / 2011
The AEMPS allows the placing on the market and marketing Octagamocta batches of 50 mg / ml and 100 mg / ml to meet the requirements set by the CHMP.
The English Agency for Medicines and Medical Devices (AEMPS) ordered the withdrawal of all batches of Octagamocta (human immunoglobulin) 5% and 10% (Octapharma SA) dated September 24, 20101.2.
The withdrawal was caused by the increase in reports of thromboembolic events detected in Europe during the second and third quarter of 2010.
were evaluated available data on the quality and safety of Octagamocta and are being analyzed thromboembolic causes of these effects by the regulatory authorities in Europe.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines, scientific committee consisting of representatives of all European national agencies, has recommended the lifting of the suspension Octagam marketing (5% and 10%) of Octapharma (Octagamocta) and the return of this product in the market European Union, following the implementation of improvements in the production process that would meet the required quality standards and other preventive measures and subsequent surveillance studies (April 14, 2011) 3.
The AEMPS thus allowing the placing on the market and marketing Octagamocta batches (5% and 10%) which satisfies with the requirements set by the CHMP.
References
ª 1.2 Extension of pharmaceutical warning No 26/10 - OCTAGAMOCTA 50 mg / ml solution for infusion (NR: 66 404) and OCTAGAMOCTA 100 mg / ml solution for infusion (NR: 71 501). English Agency of Medicines and Health Products (Competent Authority). Published online at: http://www.aemps.es/actividad/alertas/usoHumano/calidad/2010/calidad_26-10_ampliacion2.htm (Access revised May 16, 2011)
2.Not Information on withdrawal Octagamocta all lots of 50 mg / ml and 100 mg / ml for an increased risk of thromboembolic events. English Agency of Medicines and Health Products (Competent Authority). Published online at: http://www.aemps.es/actividad/alertas/usoHumano/seguridad/2010/NI_2010-13_octagamocta.htm (Access revised May 16, 2011)
3.European Medicines Agency Recommends or lifting of suspension of Octagam. European Medicines Agency. Published online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/04/news_detail_001242.jsp&murl = menus / news_and_events / news_and_events.jsp & mid = WC0b01ac058004d5c1 (Access revised May 16, 2011)
Date updated: May 18, 2011
Category: DRUGS FOR HUMAN USE.
Reference: MUH, 7 / 2011
The AEMPS allows the placing on the market and marketing Octagamocta batches of 50 mg / ml and 100 mg / ml to meet the requirements set by the CHMP.
The English Agency for Medicines and Medical Devices (AEMPS) ordered the withdrawal of all batches of Octagamocta (human immunoglobulin) 5% and 10% (Octapharma SA) dated September 24, 20101.2.
The withdrawal was caused by the increase in reports of thromboembolic events detected in Europe during the second and third quarter of 2010.
were evaluated available data on the quality and safety of Octagamocta and are being analyzed thromboembolic causes of these effects by the regulatory authorities in Europe.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines, scientific committee consisting of representatives of all European national agencies, has recommended the lifting of the suspension Octagam marketing (5% and 10%) of Octapharma (Octagamocta) and the return of this product in the market European Union, following the implementation of improvements in the production process that would meet the required quality standards and other preventive measures and subsequent surveillance studies (April 14, 2011) 3.
The AEMPS thus allowing the placing on the market and marketing Octagamocta batches (5% and 10%) which satisfies with the requirements set by the CHMP.
References
ª 1.2 Extension of pharmaceutical warning No 26/10 - OCTAGAMOCTA 50 mg / ml solution for infusion (NR: 66 404) and OCTAGAMOCTA 100 mg / ml solution for infusion (NR: 71 501). English Agency of Medicines and Health Products (Competent Authority). Published online at: http://www.aemps.es/actividad/alertas/usoHumano/calidad/2010/calidad_26-10_ampliacion2.htm (Access revised May 16, 2011)
2.Not Information on withdrawal Octagamocta all lots of 50 mg / ml and 100 mg / ml for an increased risk of thromboembolic events. English Agency of Medicines and Health Products (Competent Authority). Published online at: http://www.aemps.es/actividad/alertas/usoHumano/seguridad/2010/NI_2010-13_octagamocta.htm (Access revised May 16, 2011)
3.European Medicines Agency Recommends or lifting of suspension of Octagam. European Medicines Agency. Published online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/04/news_detail_001242.jsp&murl = menus / news_and_events / news_and_events.jsp & mid = WC0b01ac058004d5c1 (Access revised May 16, 2011)
Date updated: May 18, 2011
Wednesday, May 18, 2011
Stomach Bug Burp Fart
vs WE ALSO, ALL THE STREET!. QUIJANO
A request for hearing, although a week ago I'm living emotionally the hardest moments of my life, I bite the bullet and I leave my thoughts on what is happening on the 15th day of May in the Puerta del Sol in Madrid and, by contagion, in other cities in Spain. Insist that it is a very personal reflection and accelerated, with whom he does not have to agree Bitibajk other members not involved lately in the blog, and maybe some ideas or arguments should be qualified or depth.
commented that a few posts ago I did not trust these lateral movements that have emerged in a supposedly spontaneous in recent months that they want to appear an equal distance from both the right and the political left, but actually reflect a political strategy seems orchestrated environment from the Communist Party and other left-wing groups. Simply enter webs are not votes or Future Youth Without (not so much of Real Democracy and ) to check it, or just check what characters and associations came to the demonstration on April 7 in Madrid, as well as to the day May 15 (what paint Cayo Lara and some unionists going to a demo who report a situation in which they are responsible and a system of which they are beneficiaries?).
But one thing is to identify and point to criptoimpulsor of these demonstrations, and try to find their true purpose in the short and medium term (refloat a ship that political and social unrest for years), and quite another thing is not being able to recognize that the strategy is cojonuda and that their motivation is fair. Very fair.
is true that these concentrations are ragged Appreciation and of every size and color, so what?. Do anti-abortion demonstrations in recent years, or who have been held for victims of terrorism were not cheesy and full of fascists slicked peper?. Why are these demo-a priori-self more sectarian groups have turned patriots and will not be able to do some movements that want to be more open, and whose claims are at least as fair?. Could it be that someone feels closer to them than those?. If so, who do look with urgency. Personally I feel as distant from the neo-Marxist left than the right neocon, but no values \u200b\u200bor concepts in two widely-considered ideological spectrum, with whom I can relate to and so I feel morally prepared to go to both types of events. Well, today made me feel even closer to the hotbed of the Puerta del Sol than those held in the Plaza de Colon. Is it that at this point we do not know what the real fascism?. Let us recall the source of much of the historical fascist, remember the strikes in Berlin in the years 20/30. There is nothing new.
Before this I believe no such revolutionary who says you can stay idle. We do not know how to conclude these concentrations. As I write these lines, the Central Electoral Board has banned the concentration in the Puerta del Sol may be dissolved in the next few hours based on the new Mamluk Smite, may be reactivated after the elections on 22, may resist pressure. But, as it may, in my opinion, I think we should join the protests, both collectively and individually, and doing so with the spirit that inspires them theoretically, there are enough reasons and points in common to do so partisan, no "exclusive symbols, no banners, no slogans and misplaced polemic in peaceful attitude (though not peace) and ensure that they are truly cross-cutting actions. Going with the spirit that inspires and theoretically prevent a public outcry is catalyzed plural for the benefit of a few crusty. If that happens, there would be time to hoist our black flags.
already liberals and conservatives are shaking in their teletertulias because these demonstrations are swallowed up by the left sociata and this could jeopardize the triumphant election announced PP. Wow, how scary!. Have four years complained daily that people do not act, that the English did not cast us into the street, that English democracy is of poor quality and that politicians have become corrupt oligarchic caste, and when what we do and we demand a change, criticize us because this may prevent some counselor friend hair touch on Sunday. In our hands-on all-is that this phagocytosis (which is already in place) does not occur. Let us
a very remote event that, even though our presence and that of other people "not left" at these concentrations (which I know today is substantial) out moving forward with success, but taken over by the extreme left. Would that be a lot worse than Spain which has left-liberal capitalism of the last 50 years?. I doubt it.
a very remote event that, even though our presence and that of other people "not left" at these concentrations (which I know today is substantial) out moving forward with success, but taken over by the extreme left. Would that be a lot worse than Spain which has left-liberal capitalism of the last 50 years?. I doubt it.
paraphrase Calvo Sotelo, a former Spain "red", a move Spain.
And now, think you.
Mozárabivs
Mozárabivs
-------------------------------
BITIBAjK streetfighter -------------------------------
Subscribe to:
Posts (Atom)